文献速递炎症性肠病胃肠动力与功能性疾病

粪菌移植在真实世界实践中高度有效:FMT国家登记研究的初步结果

Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry.
PubMed 文献 · Gastroenterology · 2020-10-01

FMT国家登记研究前瞻性纳入北美20个中心的259例接受粪菌移植的艰难梭菌感染患者,1个月治愈率为90%(200/222),其中98%仅接受1次FMT;6个月随访中4%复发,严重症状和 hospitalization 少见,结论为FMT对CDI高度有效且安全性良好。

要点

  • 1个月治愈率为90%(200/222),其中98%(197/200)仅接受1次FMT。
  • 6个月随访中,初始治愈的112例患者有4例(4%)出现CDI复发。
  • FMT后1个月内严重症状包括腹泻5例(2%)和腹痛4例(2%),3例(1%)住院可能与FMT相关。

核心结论

  • 这项前瞻性真实世界研究显示FMT治疗CDI高度有效且安全性良好。
  • 随着登记研究扩大,计划在长期随访中评估新发疾病,这对确定FMT的完整安全性特征很重要。

研究设计与样本

  • FMT国家登记研究为前瞻性真实世界研究,纳入北美临床实践中接受FMT的患者。
  • 参与研究者将去标识化数据录入在线平台,包括FMT方案、基线特征、CDI治愈与复发及短期和长期安全性结局。
  • 首批在20个中心入组的259例参与者中,222例完成1个月短期随访,123例随访至6个月;171例(66%)为女性。

主要发现

  • 所有FMT均用于CDI,249例(96%)使用未知供者(如粪便库)。
  • 1个月治愈发生于200例患者(90%);其中197例(98%)仅接受1次FMT。
  • 在112例初始治愈并随访至6个月的患者中,4例(4%)出现CDI复发。
  • FMT后1个月内报告的严重症状包括腹泻5例(2%)和腹痛4例(2%);3例患者(1%)住院可能与FMT相关。
  • 6个月时,新诊断肠易激综合征2例(1%),炎症性肠病2例(1%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Fecal microbiota transplantation (FMT) is used commonly for treatment of Clostridioides difficile infections (CDIs), although prospective safety data are limited and real-world FMT practice and outcomes are not well described. The FMT National Registry was designed to assess FMT methods and both safety and effectiveness outcomes from North American FMT providers. METHODS: Patients undergoing FMT in clinical practices across North America were eligible. Participating investigators enter de-identified data into an online platform, including FMT protocol, baseline patient characteristics, CDI cure and recurrence, and short and long-term safety outcomes. RESULTS: Of the first 259 participants enrolled at 20 sites, 222 had completed short-term follow-up at 1 month and 123 had follow-up to 6 months; 171 (66%) were female. All FMTs were done for CDI and 249 (96%) used an unknown donor (eg, stool bank). One-month cure occurred in 200 patients (90%); of these, 197 (98%) received only 1 FMT. Among 112 patients with initial cure who were followed to 6 months, 4 (4%) had CDI recurrence. Severe symptoms reported within 1-month of FMT included diarrhea (n = 5 [2%]) and abdominal pain (n = 4 [2%]); 3 patients (1%) had hospitalizations possibly related to FMT. At 6 months, new diagnoses of irritable bowel syndrome were made in 2 patients (1%) and inflammatory bowel disease in 2 patients (1%). CONCLUSIONS: This prospective real-world study demonstrated high effectiveness of FMT for CDI with a good safety profile. Assessment of new conditions at long-term follow-up is planned as this registry grows and will be important for determining the full safety profile of FMT.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Kelly CR, Yen EF, Grinspan AM, et al. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2020. PMID: 33011173. doi:10.1053/j.gastro.2020.09.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。